These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35298841)

  • 1. Plasma procurement and plasma product safety in light of the COVID-19 pandemic from the perspective of the plasma industry.
    Turecek PL; Hibbett D; Kreil TR
    Vox Sang; 2022 Jun; 117(6):780-788. PubMed ID: 35298841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
    Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Chai KL; Valk SJ; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD013600. PubMed ID: 32648959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma.
    Razumikhin M; Smolyanova T; Nikolaeva A; Orlova E; Ivanov A; Belyakova O; Vyaznikova T; Selezneva N; Perevozchikov A; Sokolova A; Zubkova N; Efimova I; Dolzhikova I; Logunov D; Sakanjan E
    Immunotherapy; 2022 Oct; 14(14):1133-1147. PubMed ID: 35892311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convalescent plasma and hyperimmune globulin therapy in COVID-19.
    Cagdas D
    Expert Rev Clin Immunol; 2021 Apr; 17(4):309-316. PubMed ID: 33620014
    [No Abstract]   [Full Text] [Related]  

  • 9. Antibody Therapy for COVID-19: Categories, Pros, and Cons.
    Zare Marzouni H; Rahbar M; Seddighi N; Nabizadeh M; Meidaninikjeh S; Sabouni N
    Viral Immunol; 2022 Oct; 35(8):517-528. PubMed ID: 36201297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks.
    Wooding DJ; Bach H
    Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoting access to COVID-19 convalescent plasma in low- and middle-income countries.
    Bloch EM; Goel R; Montemayor C; Cohn C; Tobian AAR
    Transfus Apher Sci; 2021 Feb; 60(1):102957. PubMed ID: 32972861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-SARS-CoV-2 hyperimmune plasma workflow.
    Annamaria P; Eugenia Q; Paolo S
    Transfus Apher Sci; 2020 Oct; 59(5):102850. PubMed ID: 32540345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
    Tirnea L; Bratosin F; Vidican I; Cerbu B; Turaiche M; Timircan M; Margan MM; Marincu I
    Medicina (Kaunas); 2021 Mar; 57(3):. PubMed ID: 33799535
    [No Abstract]   [Full Text] [Related]  

  • 15. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.
    Jin C; Yu B; Zhang J; Wu H; Zhou X; Yao H; Liu F; Lu X; Cheng L; Jiang M; Wu N
    BMC Infect Dis; 2021 Apr; 21(1):357. PubMed ID: 33863281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Chai KL; Valk SJ; Piechotta V; Kimber C; Monsef I; Doree C; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2020 Oct; 10():CD013600. PubMed ID: 33044747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
    Hosseini P; Rahimi H; Najafabadi MM; Ghorbani A; Najafabadi SK; Faridzadeh A; Arabpour J; Khormali E; Deravi N
    Acta Med Indones; 2021 Jan; 53(1):86-95. PubMed ID: 33818411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2.
    Taşlı NP; Gönen ZB; Kırbaş OK; Gökdemir NS; Bozkurt BT; Bayrakcı B; Sağraç D; Taşkan E; Demir S; Ekimci Gürcan N; Bayındır Bilgiç M; Bayrak ÖF; Yetişkin H; Kaplan B; Pavel STI; Dinç G; Serhatlı M; Çakırca G; Eken A; Aslan V; Yay M; Karakukcu M; Unal E; Gül F; Basaran KE; Ozkul Y; Şahin F; Jones OY; Tekin Ş; Özdarendeli A; Cetin M
    Front Immunol; 2022; 13():824378. PubMed ID: 35401544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of 52 240 source plasma donors of convalescent COVID-19 plasma: Sex, ethnicity, and age association with initial antibody levels and rate of dissipation.
    Schmidt AE; Vogel P; Chastain CA; Barnes T; Roth NJ; Simon TL
    J Clin Apher; 2022 Oct; 37(5):449-459. PubMed ID: 35815776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early safety indicators of COVID-19 convalescent plasma in 5000 patients.
    Joyner MJ; Wright RS; Fairweather D; Senefeld JW; Bruno KA; Klassen SA; Carter RE; Klompas AM; Wiggins CC; Shepherd JR; Rea RF; Whelan ER; Clayburn AJ; Spiegel MR; Johnson PW; Lesser ER; Baker SE; Larson KF; Ripoll JG; Andersen KJ; Hodge DO; Kunze KL; Buras MR; Vogt MN; Herasevich V; Dennis JJ; Regimbal RJ; Bauer PR; Blair JE; Van Buskirk CM; Winters JL; Stubbs JR; Paneth NS; Verdun NC; Marks P; Casadevall A
    J Clin Invest; 2020 Sep; 130(9):4791-4797. PubMed ID: 32525844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.